药品名称 | REYATAZ | 申请号 | 021567 | 产品号 | 001 | 活性成分 | ATAZANAVIR SULFATE | 市场状态 | 停止上市 | 剂型或给药途径 | CAPSULE;ORAL | 规格 | EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | 治疗等效代码 | | 参比药物 | 否 | 批准日期 | 2003/06/20 | 申请机构 | BRISTOL MYERS SQUIBB CO
| 化学类型 | New molecular entity (NME) | 审评分类 | Priority review drug |
|
|
|
与本品相关的市场独占权保护信息 | 独占权代码 | 失效日期 | 无 | 历史市场独占权保护信息 | D-116 | 2011/09/30 | D-130 | 2014/02/04 | D-89 | 2007/07/06 | NCE | 2008/06/20 | NPP | 2011/03/25 |
|
与药品注册相关的信息 | 申请号 | 修订号 | 审批结论 | 公开文档类型 | 文档创建时间 | 获取文档 | 021567 | 039 | AP | Letter | 2016/09/20 | 下载 | 021567 | 039 | AP | Label | 2016/09/20 | 下载 | 021567 | 038 | AP | Letter | 2015/09/28 | 下载 | 021567 | 038 | AP | Label | 2015/12/10 | 下载 | 021567 | 037 | AP | Letter | 2015/04/01 | 下载 | 021567 | 037 | AP | Label | 2015/04/02 | 下载 | 021567 | 036 | AP | Letter | 2015/02/27 | 下载 | 021567 | 035 | AP | Review | 2015/04/07 | 下载 | 021567 | 035 | AP | Summary Review | 2015/04/07 | 下载 | 021567 | 035 | AP | Letter | 2014/06/03 | 下载 | 021567 | 035 | AP | Label | 2014/06/03 | 下载 | 021567 | 033 | AP | Letter | 2013/08/20 | 下载 | 021567 | 033 | AP | Label | 2013/08/21 | 下载 | 021567 | 032 | AP | Letter | 2013/08/20 | 下载 | 021567 | 032 | AP | Label | 2013/08/21 | 下载 | 021567 | 031 | AP | Letter | 2013/02/04 | 下载 | 021567 | 028 | AP | Letter | 2012/03/16 | 下载 | 021567 | 028 | AP | Label | 2012/03/16 | 下载 | 021567 | 027 | AP | Letter | 2012/02/23 | 下载 | 021567 | 027 | AP | Label | 2012/02/24 | 下载 | 021567 | 026 | AP | Label | 2011/10/17 | 下载 | 021567 | 026 | AP | Letter | 2011/10/19 | 下载 | 021567 | 025 | AP | Label | 2011/02/09 | 下载 | 021567 | 025 | AP | Letter | 2011/02/10 | 下载 | 021567 | 025 | AP | Review | 2015/07/20 | 下载 | 021567 | 023 | AP | Letter | 2010/04/29 | 下载 | 021567 | 023 | AP | Label | 2010/05/03 | 下载 | 021567 | 022 | AP | Letter | 2010/01/28 | 下载 | 021567 | 022 | AP | Label | 2010/01/24 | 下载 | 021567 | 019 | AP | Letter | 2010/01/25 | 下载 | 021567 | 019 | AP | Label | 2009/11/23 | 下载 | 021567 | 019 | AP | Review | 2014/08/05 | 下载 | 021567 | 018 | AP | Letter | 2008/02/22 | 下载 | 021567 | 018 | AP | Label | 2008/02/25 | 下载 | 021567 | 017 | AP | Letter | 2008/10/02 | 下载 | 021567 | 017 | AP | Label | 2008/10/03 | 下载 | 021567 | 016 | AP | Letter | 2008/08/20 | 下载 | 021567 | 016 | AP | Label | 2008/08/26 | 下载 | 021567 | 015 | AP | Label | 2008/03/27 | 下载 | 021567 | 015 | AP | Letter | 2008/03/28 | 下载 | 021567 | 014 | AP | Label | 2008/01/08 | 下载 | 021567 | 014 | AP | Letter | 2008/01/09 | 下载 | 021567 | 012 | AP | Letter | 2007/03/31 | 下载 | 021567 | 012 | AP | Label | 2007/03/31 | 下载 | 021567 | 011 | AP | Label | 2006/08/11 | 下载 | 021567 | 011 | AP | Letter | 2006/08/14 | 下载 | 021567 | 009 | AP | Label | 2006/10/18 | 下载 | 021567 | 009 | AP | Letter | 2006/10/23 | 下载 | 021567 | 008 | AP | Letter | 2006/08/14 | 下载 | 021567 | 008 | AP | Label | 2006/08/11 | 下载 | 021567 | 007 | AP | Label | 2006/01/25 | 下载 | 021567 | 007 | AP | Letter | 2006/01/30 | 下载 | 021567 | 005 | AP | Letter | 2005/07/21 | 下载 | 021567 | 005 | AP | Label | 2005/07/21 | 下载 | 021567 | 004 | AP | Letter | 2004/10/08 | 下载 | 021567 | 004 | AP | Label | 2004/10/08 | 下载 | 021567 | 002 | AP | Label | 2004/07/07 | 下载 | 021567 | 002 | AP | Letter | 2004/07/07 | 下载 | 021567 | 001 | AP | Letter | 2004/03/19 | 下载 | 021567 | 001 | AP | Label | 2004/04/05 | 下载 | 021567 | 000 | AP | Label | 2003/07/08 | 下载 | 021567 | 000 | AP | Letter | 2003/08/06 | 下载 | 021567 | 000 | AP | Review | 2003/09/09 | 下载 |
|
药品注册审批历史信息 | 申请号 | 修订号 | 审批结论 | 审批日期 | 审批内容 | 021567 | 039 | AP | 2016/09/15 | Labeling Revision | 021567 | 038 | AP | 2015/09/24 | Efficacy Supplement with Clinical Data to Support | 021567 | 037 | AP | 2015/03/27 | Labeling Revision | 021567 | 036 | AP | 2015/02/26 | Labeling Revision | 021567 | 036 | AP | 2015/02/26 | Labeling Revision | 021567 | 035 | AP | 2014/06/02 | Efficacy Supplement with Clinical Data to Support | 021567 | 034 | AP | 2014/02/26 | Manufacturing Change or Addition | 021567 | 033 | AP | 2013/08/15 | Labeling Revision | 021567 | 032 | AP | 2013/08/15 | Labeling Revision | 021567 | 031 | AP | 2013/01/30 | Labeling Revision | 021567 | 028 | AP | 2012/03/14 | Labeling Revision | 021567 | 027 | AP | 2012/02/17 | Labeling Revision | 021567 | 026 | AP | 2011/10/17 | New Dosage Regimen | 021567 | 025 | AP | 2011/02/04 | Patient Population Altered | 021567 | 023 | AP | 2010/04/26 | Labeling Revision | 021567 | 022 | AP | 2010/01/22 | Labeling Revision | 021567 | 019 | AP | 2009/11/05 | Efficacy Supplement with Clinical Data to Support | 021567 | 018 | AP | 2008/02/20 | Labeling Revision | 021567 | 017 | AP | 2008/09/30 | Patient Population Altered | 021567 | 016 | AP | 2008/08/15 | Labeling Revision | 021567 | 015 | AP | 2008/03/25 | Patient Population Altered | 021567 | 014 | AP | 2007/12/21 | Labeling Revision | 021567 | 012 | AP | 2007/03/22 | Labeling Revision | 021567 | 011 | AP | 2006/08/09 | Labeling Revision | 021567 | 009 | AP | 2006/10/16 | Formulation Revision | 021567 | 008 | AP | 2006/08/09 | Labeling Revision | 021567 | 007 | AP | 2006/01/25 | Labeling Revision | 021567 | 005 | AP | 2005/07/18 | Labeling Revision | 021567 | 004 | AP | 2004/10/05 | Labeling Revision | 021567 | 002 | AP | 2004/07/06 | New Dosage Regimen | 021567 | 001 | AP | 2004/03/16 | Labeling Revision | 021567 | 000 | AP | 2003/06/20 | Approval |
|